In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ≥10g/dL following treatment with eculizumab or ravulizumab)1,2PNH is a rare, chronic and serious complement-mediated blood disorder, characterized by hemolysis, anemia, thrombosis and other symptoms, and patients are often treated with anti-C5 therapies3-5Findings from APPULSE-P ...

Novartis (NVS) has entered into a global license and collaboration agreement with PTC Therapeutics (PTCT) for the latter’s Huntington's disease candidate to strengthen NVS’ neuroscience pipeline.NVS also announced a collaboration with Olema Pharmaceuticals, Inc. (OLMA) for a breast cancer drug.Year to date, shares of Novartis have risen 3.8% compared with the industry’s growth of 8.9%.Image Source: Zacks Investment ResearchNVS’ Licensing Deal With PTCTNovartis will in-license PTC Therapeutics’ PTC518.  The ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Novartis (NVS) announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a broad population.The EC has approved Kisqali in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence.Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that helps slow the progression of ...

Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in patients with stage II or III HR+/HER2- early breast cancer (EBC), consistent across all subgroups1,2With this broad indication, nearly twice as many EBC patients in Europe, including those with node-negative disease, could now be eligible for treatment with Kisqali to help reduce their risk of recurrence3Despite ET ...

Novartis (NVS) announced that it has increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with the previous estimate of 5%.The rise in guidance was due to the strong momentum of NVS’ key drugs and its upcoming launches.Shares of Novartis have risen 4% year to date compared with the industry’s growth of 4.8%.Image Source: Zacks Investment ResearchNVS Raises Mid-Term OutlookFor 2024-2029, sales are ex ...

Core Viewpoint - Novartis has upgraded its mid-term sales guidance, expecting a compound annual growth rate (CAGR) of +6% for the period 2023-2028, driven by strong business momentum and upcoming product launches [1][2]. Sales Guidance - The previous sales CAGR guidance of +5% for 2023-2028 has been increased to +6%, reflecting robust growth drivers and anticipated launches with expected US exclusivity in the 2030s or later [1]. - For the period 2024-2029, Novartis expects a sales growth of +5% CAGR, using strong performance in 2024 as a base year [2]. Product Pipeline and Growth Drivers - Novartis has identified 8 in-market brands with peak sales potential ranging from USD 3 billion to USD 8 billion, alongside over 15 near-term submission-enabling readouts [1]. - The company has more than 30 high-value medicines in its pipeline, which are expected to support continued mid-single-digit sales growth beyond 2029 [1][3]. Strategic Focus and Acquisitions - The company has completed its transformation into a pure-play innovative medicines company, enhancing its capabilities in core therapeutic areas and technology platforms [3]. - Novartis has executed over 30 strategic deals in the last two years, focusing on exploratory to preclinical stages, including the acquisition of Kate Therapeutics and a collaboration with Ratio Therapeutics [3].

The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration of products in LMICs, and inclusive business model to improve access to products in multiple countries were all highlighted as Best Practice across the industry Novartis has risen three places to secure the top spot on the 2024 Access to Medicine Index Basel, November 19, 2024 – Novartis has ranked first in the ...

Ratio to receive upfront, and potential milestones and tiered royalty paymentsBOSTON, Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). The collaboration leverages Ratio's radioligand therapy discovery and develop ...

The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts ...